GTAB B Share Price Performance
SEK 1.97
0.30 (17.66%)
Price SEK 1.97
Share PriceSEK 1.97
Glycorex Transplantation AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
GTAB B Community Narratives
There are no narratives available yet.
Recent GTAB B News & Updates
Glycorex Transplantation AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 28, 2025
- Earnings per share (EPS)
- -0.10
- Gross Margin
- 82.41%
- Net Profit Margin
- -21.18%
- Debt/Equity Ratio
- 0.3%
Glycorex Transplantation AB (publ) Competitors
Snowflake Analysis
About GTAB B
- Founded
- 1995
- Employees
- 20
- CEO
- WebsiteView website
Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company’s principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures. It serves in Europe, Austria, Germany, the Netherlands, the United Kingdom, Canada, and Spain. Glycorex Transplantation AB (publ) was incorporated in 1995 and is headquartered in Lund, Sweden.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Swedish Market Performance
- 7 Days: -1.1%
- 3 Months: 1.2%
- 1 Year: -1.3%
- Year to Date: 2.0%
Over the last 7 days, the market has remained flat, although notably the Energy sector declined by 3.8%. As for the longer term, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›